Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer

Fig. 4

IRF8 is a predictive marker for complete pathological response to trastuzumab and FAC treatment in HER2+ and TNBC. IRF8 expression in non-responder (NR) and responder (R) patients to the different therapeutic regimes. ER+ BC: endocrine therapy treatment (n = 60), TNBC: FAC (n = 54), CMF (n = 28) or anthracycline (n = 473) treatments, and HER2+ BC: trastuzumab treatment (n = 66). Endocrine therapy involves: tamoxifen and aromatase inhibitors. FAC: fluorouracil, adriamycin (doxorubicin), and cytoxan (cyclophosphamide). CMF: cyclophosphamide, methotrexate, and fluorouracil

Back to article page